Idorsia Pharmaceuticals Ltd.
Clinical trials sponsored by Idorsia Pharmaceuticals Ltd., explained in plain language.
A biopharmaceutical company focused on discovering and developing small-molecule drugs for various diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill aims to bring back color to vitiligo skin Results expected Jun 2027 (estimated)
-
Can a new pill stop fatty buildup in fabry disease?
Disease control Not yet recruitingThis trial tests whether the drug lucerastat can reduce the buildup of a fatty substance called Gb3 in the kidneys of adult men with Fabry disease who have not received prior treatment. Participants will take lucerastat daily for 18 months and undergo kidney biopsies to measure c…
Phase 3 • Sponsor: Idorsia Pharmaceuticals Ltd. • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New pill aims to bring back color to vitiligo skin
Disease control Not yet recruitingThis phase 2a trial tests whether a daily pill called ACT-777991 can help return color to the face of adults with non-segmental vitiligo. About 30 participants will take either the drug or a placebo for 24 weeks. Researchers will measure changes in skin color using a standard sco…
Phase 2 • Sponsor: Idorsia Pharmaceuticals Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC